Michaela Mattheus
Overview
Explore the profile of Michaela Mattheus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
6890
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petrie M, Udell J, Anker S, Harrington J, Jones W, Mattheus M, et al.
Eur J Heart Fail
. 2024 Dec;
PMID: 39725521
Aims: In the EMPACT-MI trial, empagliflozin reduced heart failure (HF) hospitalizations but not mortality in acute myocardial infarction (MI). Contemporary reports of clinical event rates with and without type 2...
2.
Massey R, Chen Y, Panova-Noeva M, Mattheus M, Siddiqui M, Schloot N, et al.
Cardiovasc Diabetol
. 2024 Jul;
23(1):256.
PMID: 39014446
Background: BMI variability has been associated with increased cardiovascular disease risk in individuals with type 2 diabetes, however comparison between clinical studies and real-world observational evidence has been lacking. Furthermore,...
3.
Fitchett D, Zinman B, Inzucchi S, Wanner C, Anker S, Pocock S, et al.
Cardiovasc Diabetol
. 2024 Jul;
23(1):248.
PMID: 38992713
Background: The effect of empagliflozin, a sodium-glucose-co-transporter-2 inhibitor, on risk for myocardial infarction has not been fully characterized. Methods: This study comprised prespecified and post-hoc analyses of the EMPA-REG OUTCOME...
4.
Inzucchi S, Wanner C, Fitchett D, Zinman B, Anker S, Pocock S, et al.
Diabetes Res Clin Pract
. 2024 May;
212:111715.
PMID: 38777127
In EMPA-REG OUTCOME, empagliflozin reduced the composite of total events leading to/prolonging hospitalisation for any cause and all-cause mortality by 24 % versus placebo in patients with T2DM and ASCVD,...
5.
Udell J, Petrie M, Jones W, Anker S, Harrington J, Mattheus M, et al.
J Am Coll Cardiol
. 2024 Apr;
83(23):2233-2246.
PMID: 38588929
Background: Empagliflozin reduces the risk of heart failure (HF) hospitalizations but not all-cause mortality when started within 14 days of acute myocardial infarction (AMI). Objectives: This study sought to evaluate...
6.
Butler J, Jones W, Udell J, Anker S, Petrie M, Harrington J, et al.
N Engl J Med
. 2024 Apr;
390(16):1455-1466.
PMID: 38587237
Background: Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety and...
7.
Hernandez A, Udell J, Jones W, Anker S, Petrie M, Harrington J, et al.
Circulation
. 2024 Apr;
149(21):1627-1638.
PMID: 38581389
Background: Empagliflozin reduces the risk of heart failure (HF) events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF irrespective of ejection fraction....
8.
Koneswarakantha B, Adyanthaya R, Emerson J, Collin F, Keller A, Mattheus M, et al.
Ther Innov Regul Sci
. 2024 Apr;
58(4):591-599.
PMID: 38564178
Accurate and timely reporting of adverse events (AEs) in clinical trials is crucial to ensuring data integrity and patient safety. However, AE under-reporting remains a challenge, often highlighted in Good...
9.
Hadjadj S, Cooper M, Steubl D, Petrini M, Hantel S, Mattheus M, et al.
Kidney Med
. 2024 Feb;
6(3):100783.
PMID: 38419787
Rationale & Objective: Kidney function progressively declines in most patients with type 2 diabetes (T2DM). Many develop progressive chronic kidney disease (CKD), but some experience a more rapid decline, with...
10.
Wanner C, Nangaku M, Kraus B, Zinman B, Mattheus M, Hantel S, et al.
Nephrol Dial Transplant
. 2024 Feb;
39(9):1504-1513.
PMID: 38323492
Introduction: Mechanisms underlying kidney benefits with sodium-glucose cotransporter-2 (SGLT2) inhibition in heart failure and/or type 2 diabetes (T2D) with established cardiovascular disease are currently unclear. Methods: We evaluated post hoc...